Interesting ImagesSuccessful Intra-arterial Peptide Receptor Radionuclide Therapy of DOTATOC-Negative High-Grade Liver Metastases of a Pancreatic Neuroendocrine Neoplasm Using 177Lu-DOTA-LM3 A Somatostatin Receptor AntagonistZhang, Jingjing MD, PhD; Kulkarni, Harshad R. MD; Singh, Aviral MD, MSc; Baum, Richard P. MD, PhDAuthor Information From the THERANOSTICS Center for Molecular Radiotherapy and Precision Oncology, Zentralklinik Bad Berka, Bad Berka, Germany. Received for publication July 19, 2019; revision accepted October 19, 2019. Conflicts of interest and sources of funding: none declared. Correspondence to: Jingjing Zhang MD, PhD, THERANOSTICS Center for Molecular, Radiotherapy and Precision Oncology, Zentralklinik Bad Berka, Robert-Koch-Allee 9, 99437, Bad Berka, Germany. E-mail: email@example.com. Online date: January 30, 2019 Clinical Nuclear Medicine: March 2020 - Volume 45 - Issue 3 - p e165-e168 doi: 10.1097/RLU.0000000000002906 Buy Metrics Abstract Radiolabeled somatostatin receptor (SSTR) antagonists have shown promise for imaging neuroendocrine neoplasms and the superiority to SSTR agonists, with lower liver background especially for the sensitive detection of liver metastases, higher tumor-to-background ratio, and favorable pharmacokinetics. The clinical data of radiolabeled SSTR antagonists for therapy are still limited. We report our experience treating a young patient with DOTATOC-negative high-grade liver metastases of a pancreatic neuroendocrine neoplasm who underwent intra-arterial peptide receptor radionuclide therapy using SSTR antagonist 177Lu-DOTA-LM3, demonstrating an excellent response, nearly complete remission according to molecular imaging criteria and morphological partial remission, without any significant toxicity. Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.